Merck & Co Stock

Merck & Co Revenue 2024

Merck & Co Revenue

64.75 B USD

Ticker

MRK

ISIN

US58933Y1055

WKN

A0YD8Q

In 2024, Merck & Co's sales reached 64.75 B USD, a 7.71% difference from the 60.12 B USD sales recorded in the previous year.

The Merck & Co Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e78.3656,41
2028e80.3854,99
2027e77.0657,36
2026e73.160,46
2025e68.9864,08
2024e64.7568,27
202360.1273,53
202259.2870,98
202148.772,81
202041.5272,10
201939.1271,73
201842.2969,11
201740.1268,50
201639.8166,08
201539.563,22
201442.2464,05
201344.0363,61
201247.2765,21
201148.0564,89
201045.9960,00
200927.4367,12
200823.8576,59
200724.274,62
200622.6473,49
200522.0176,61
200422.9778,38

Merck & Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Merck & Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Merck & Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Merck & Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Merck & Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Merck & Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Merck & Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Merck & Co’s growth potential.

Merck & Co Revenue, EBIT and net profit per share

DateMerck & Co RevenueMerck & Co EBITMerck & Co Net Income
2029e78.36 B undefined0 undefined30.72 B undefined
2028e80.38 B undefined35.87 B undefined31.99 B undefined
2027e77.06 B undefined34.68 B undefined29.97 B undefined
2026e73.1 B undefined33.21 B undefined27.47 B undefined
2025e68.98 B undefined30.56 B undefined24.9 B undefined
2024e64.75 B undefined25.29 B undefined20.65 B undefined
202360.12 B undefined4.07 B undefined365 M undefined
202259.28 B undefined20.31 B undefined14.52 B undefined
202148.7 B undefined15.57 B undefined13.05 B undefined
202041.52 B undefined10.93 B undefined7.07 B undefined
201939.12 B undefined10.09 B undefined9.84 B undefined
201842.29 B undefined11.31 B undefined6.22 B undefined
201740.12 B undefined9.96 B undefined2.39 B undefined
201639.81 B undefined9.94 B undefined3.92 B undefined
201539.5 B undefined8.61 B undefined4.44 B undefined
201442.24 B undefined9.35 B undefined11.92 B undefined
201344.03 B undefined9.22 B undefined4.4 B undefined
201247.27 B undefined10.5 B undefined6.17 B undefined
201148.05 B undefined10.1 B undefined6.26 B undefined
201045.99 B undefined6.75 B undefined859 M undefined
200927.43 B undefined4.7 B undefined12.85 B undefined
200823.85 B undefined6.21 B undefined7.79 B undefined
200724.2 B undefined5.94 B undefined3.27 B undefined
200622.64 B undefined3.74 B undefined4.43 B undefined
200522.01 B undefined5.88 B undefined4.63 B undefined
200422.97 B undefined6.76 B undefined5.83 B undefined

Merck & Co stock margins

The Merck & Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merck & Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merck & Co.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Merck & Co's sales revenue. A higher gross margin percentage indicates that the Merck & Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Merck & Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Merck & Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Merck & Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Merck & Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Merck & Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Merck & Co Margin History

Merck & Co Gross marginMerck & Co Profit marginMerck & Co EBIT marginMerck & Co Profit margin
2029e73.53 %0 %39.2 %
2028e73.53 %44.62 %39.81 %
2027e73.53 %45 %38.89 %
2026e73.53 %45.42 %37.58 %
2025e73.53 %44.3 %36.1 %
2024e73.53 %39.07 %31.89 %
202373.53 %6.76 %0.61 %
202270.98 %34.26 %24.49 %
202172.81 %31.96 %26.79 %
202072.1 %26.31 %17.02 %
201971.73 %25.78 %25.16 %
201869.11 %26.74 %14.71 %
201768.5 %24.82 %5.97 %
201666.08 %24.98 %9.85 %
201563.22 %21.79 %11.25 %
201464.05 %22.13 %28.22 %
201363.61 %20.93 %10 %
201265.21 %22.21 %13.04 %
201164.89 %21.02 %13.02 %
201060 %14.67 %1.87 %
200967.12 %17.13 %46.86 %
200876.59 %26.05 %32.65 %
200774.62 %24.56 %13.5 %
200673.49 %16.54 %19.59 %
200576.61 %26.7 %21.04 %
200478.38 %29.42 %25.38 %

Merck & Co Aktienanalyse

What does Merck & Co do?

The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards. Merck & Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Merck & Co's Sales Figures

The sales figures of Merck & Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Merck & Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Merck & Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Merck & Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Merck & Co stock

How much revenue did Merck & Co generate this year?

Merck & Co has achieved a revenue of 64.75 B USD this year.

How much was the turnover of the company Merck & Co compared to the previous year?

The revenue of Merck & Co has increased by 7.71% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Merck & Co?

The revenue of Merck & Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Merck & Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Merck & Co so important for investors?

The revenue of Merck & Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Merck & Co pay?

Over the past 12 months, Merck & Co paid a dividend of 2.96 USD . This corresponds to a dividend yield of about 2.5 %. For the coming 12 months, Merck & Co is expected to pay a dividend of 3.37 USD.

What is the dividend yield of Merck & Co?

The current dividend yield of Merck & Co is 2.5 %.

When does Merck & Co pay dividends?

Merck & Co pays a quarterly dividend. This is distributed in the months of January, April, July, October.

How secure is the dividend of Merck & Co?

Merck & Co paid dividends every year for the past 26 years.

What is the dividend of Merck & Co?

For the upcoming 12 months, dividends amounting to 3.37 USD are expected. This corresponds to a dividend yield of 2.85 %.

In which sector is Merck & Co located?

Merck & Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Merck & Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Merck & Co from 10/7/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did Merck & Co pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of Merck & Co in the year 2023?

In the year 2023, Merck & Co distributed 2.8 USD as dividends.

In which currency does Merck & Co pay out the dividend?

The dividends of Merck & Co are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Merck & Co stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Merck & Co

Our stock analysis for Merck & Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck & Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.